Bariatric surgery is recognized as a highly effective method in combating obesity; however, it does not guarantee a definitive cure for the condition. It is common that years after the procedure, some patients experience weight regain or fail to achieve the expected weight loss. In these circumstances, drugs such as semaglutide and tirzepatide, popularly called weight loss pens, can serve as support to resume weight control and, in certain situations, prevent the need for another surgical intervention.
Obesity is classified as a chronic and multifactorial disease, which implies that it does not completely disappear after surgery. Although bariatric surgery generates metabolic, hormonal, and anatomical transformations in the body, the biological factors that promote weight gain persist.
It is estimated that between 20% and 30% of individuals undergoing bariatric surgery experience clinically relevant weight regain over the years. An indicator used to measure this is the return of at least 50% of the weight lost after the operation.
View on Weight Regain
Henrique Dametto, a digestive surgeon at Einstein Israelite Hospital, emphasizes that he does not automatically consider weight gain a failure of the surgery or the patient themselves, stating that obesity is a chronic and recurrent disease. He explains that even after very efficient treatment, weight gain can occur over the years. In some cases, this may be linked to anatomical changes resulting from the surgery, requiring investigation, but most often, it is a manifestation of obesity itself.
In this scenario, anti-obesity medications administered in 'pens' come into play. Semaglutide, whose active ingredient is present in drugs like Ozempic and Wegovy, mimics the action of the GLP-1 hormone. Tirzepatide, a component of Mounjaro, produced by the pharmaceutical company Eli Lilly, acts on GLP-1 and GIP receptors, which are involved in appetite and glucose modulation. The effect of these substances is to control the feeling of satiety and appetite, helping to decrease overall caloric intake and hunger.
For people who have already undergone bariatric surgery, the mechanism of action of these medications is identical to that of those who have never had the procedure. According to Dametto, since the medications are administered subcutaneously, the anatomical changes caused by the surgery do not interfere with their absorption. These drugs can be prescribed both for those who have regained weight and for patients who have not achieved satisfactory weight loss after surgery.
Dametto points out that in various observational studies, frequent reductions in the range of 8% to 15% of body weight have been recorded in operated patients after starting treatment with such medications, although the results may vary depending on the medication, dosage, and follow-up period. However, he emphasizes the need for broader and longer-term studies to evaluate these results specifically in this population.
Prior Evaluation and Additional Care
Before prescribing pens for bariatric patients, it is crucial to investigate the reason for weight gain. This evaluation must cover eating habits, behavior, metabolic status, and any anatomical changes resulting from the operation. In some situations, there may be dilation of gastric structures or the anastomosis (the surgical connection between parts of the digestive tract), which may require an endoscopy or a new surgery.
The doctor at Einstein reinforces that the goal will never be to recommend a new surgery just because the patient has regained weight; it is imperative to identify the source of the problem to offer the most appropriate treatment, which is not always surgical in nature.
Another vital consideration before starting the use of these medications is the maintenance of muscle mass. Bariatric patients can develop nutritional deficiencies, depending on the surgical technique used, particularly regarding protein, iron, vitamin B12, and calcium. Since the pens reduce appetite and consequently food intake, it is necessary to monitor nutrient intake and ensure supplementation when necessary.
Henrique Dametto advises that regular physical exercise, especially those focused on muscle strengthening, is important for preserving muscle mass during the weight loss process. Furthermore, signs such as nausea, vomiting, and dehydration must be monitored.
Finally, the treatment does not end when the patient achieves the desired goal. Stopping the medications can lead to further weight gain; therefore, the decision to discontinue must be planned and monitored. The specialist concludes that although not everyone needs to use the medication permanently, the duration of the treatment must be personalized and its withdrawal carefully planned.



